Lisa Rydén
61 – 70 of 216
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
- Contribution to journal › Article
-
Mark
Pam50 intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more aggressive subtypes with prognostic implications
- Contribution to journal › Article
- 2020
-
Mark
Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer
- Contribution to journal › Article
-
Mark
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
- Contribution to journal › Article
-
Mark
Evolution of estrogen receptor status from primary tumors to metastasis and serially collected circulating tumor cells
- Contribution to journal › Article
-
Mark
Barriers and facilitators for individualized rehabilitation during breast cancer treatment- A focus group study exploring health care professionals' experiences
- Contribution to journal › Article
-
Mark
Whole-genome sequencing of triple negative breast cancers in a standard population-based clinical setting
(2020) UK Interdisciplinary Breast Cancer Symposium 2020 In Breast Cancer Research and Treatment 180. p.531-532
- Contribution to journal › Published meeting abstract
-
Mark
Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
- Contribution to journal › Article
-
Mark
Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. A retrospective, comprehensive survey of neo-adjuvant treated HER2-positve breast cancer in the SCAN-B project 2010-2017
(2020) San Antonio Breast Cancer Symposium, 2019 In Cancer research. Supplement 80(Issue 4 Supplement). p.1-18
- Contribution to journal › Published meeting abstract
-
Mark
The generalisability of randomised clinical trials : an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
- Contribution to journal › Article
